Can drugs help patients with lower limb ischaemia?

Area of Science:

• Vascular Medicine
• Pharmacology
• Public Health

Background:

• Symptomatic lower limb arterial disease affects 2% of individuals aged 45-60.
• The condition often follows a benign course, with 70% of patients not requiring active therapy.
• Current pharmacological interventions lack robust evidence of efficacy.

Purpose of the Study:

• To evaluate the effectiveness of various drug classes in treating lower limb arterial disease.
• To explore the potential role of long-term antiplatelet therapy in disease management.
• To assess symptomatic relief options for intermittent claudication.

Main Methods:

• Review of existing evidence on antilipaemic drugs, anticoagulants, vasodilators, rheological agents, antiplatelet drugs, and prostaglandins.
• Analysis of the aetiology of atherosclerosis, focusing on platelet/endothelial interactions.
• Consideration of symptomatic treatments like naftidrofuryl and suloctodil.

Main Results:

• No evidence supports the benefit of antilipaemic drugs, anticoagulants, vasodilators, or rheological agents.
• Initial trials of antiplatelet drugs and prostaglandins were disappointing.
• Naftidrofuryl and suloctodil may offer symptomatic relief, particularly in severe ischemia.

Conclusions:

• Current drug treatments for lower limb arterial disease provide limited benefit.
• Long-term antiplatelet therapy warrants further investigation for preventing disease progression.
• Exercise and smoking cessation are paramount and should not be superseded by medication.